Angeion begins European trials of Sentinel 2010:
This article was originally published in Clinica
Executive Summary
Angeion has begun clinical evaluation of its Sentinel 2010 implantable cardioverter defibrillator. The first device was implanted in a patient in the Czech Republic. The 60 cc 2010 series weighs 110 g and stores 5.5 minutes of ECG. It is based on the Sentinel 2000, which is currently in US clinical trials and has been audited for CE marking by TUV Product Services of Munich, Germany.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.